Pariet: Advanced Acid Control for Gastric Health
Pariet
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | 0.56 $ | 50.31 $ (0%) | 🛒 Add to cart |
| 120 | 0.53 $ | 67.08 $ 63.18 $ (6%) | 🛒 Add to cart |
| 180 | 0.50 $ | 100.62 $ 90.09 $ (10%) | 🛒 Add to cart |
| 270 | 0.48 $ | 150.93 $ 129.87 $ (14%) | 🛒 Add to cart |
| 360 | 0.47 $
Best per pill | 201.24 $ 168.48 $ (16%) | 🛒 Add to cart |
Pariet (rabeprazole sodium) is a proton pump inhibitor (PPI) designed for the effective management of acid-related gastrointestinal disorders. It works by selectively and irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This mechanism provides potent and prolonged acid control, making it a first-line therapeutic option for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Clinical studies demonstrate its rapid onset of action and consistent efficacy, with a favorable safety profile suitable for both short-term and maintenance therapy. Healthcare professionals value its predictable pharmacokinetics and minimal cytochrome P450 interactions, allowing for flexible use in diverse patient populations.
Features
- Active ingredient: Rabeprazole sodium
- Available in delayed-release tablet formulations (typically 10 mg and 20 mg)
- Designed for oral administration with enteric coating to protect against gastric acid degradation
- Rapid and sustained suppression of gastric acid production
- High bioavailability, not significantly affected by food intake
- Compatible with long-term use under medical supervision
Benefits
- Provides rapid and effective relief from heartburn, acid regurgitation, and other GERD symptoms
- Promotes healing of erosive esophagitis and reduces risk of recurrence
- Effective in eradicating Helicobacter pylori when used in combination therapy
- Reduces the risk of NSAID-induced gastric ulcers in at-risk patients
- Helps manage hypersecretory conditions like Zollinger-Ellison syndrome
- Supports improved quality of life by enabling normal dietary habits and sleep patterns
Common use
Pariet is commonly prescribed for the treatment of gastroesophageal reflux disease (GERD), including symptomatic relief and healing of erosive esophagitis. It is also used in the management of duodenal and gastric ulcers, both in active treatment and maintenance phases. Additionally, it is employed as part of combination therapy for the eradication of Helicobacter pylori infection, alongside antibiotics such as amoxicillin and clarithromycin. In cases of pathological hypersecretory conditions, including Zollinger-Ellison syndrome, it provides effective acid control. Off-label uses may include prevention of stress-related mucosal damage in critically ill patients, though this should be carefully evaluated by a healthcare provider.
Dosage and direction
The recommended dosage of Pariet varies depending on the condition being treated. For GERD, the usual adult dose is 20 mg once daily for 4-8 weeks. For maintenance therapy in healed erosive esophagitis, 10 mg or 20 mg once daily may be used. For H. pylori eradication, a dose of 20 mg twice daily is typically prescribed alongside antibiotics for 7-14 days. Tablets should be swallowed whole, without chewing or crushing, and can be taken with or without food. For patients unable to swallow tablets, the tablet may be dispersed in water and administered via nasogastric tube following specific instructions. Dosage adjustments may be necessary in patients with severe hepatic impairment.
Precautions
Patients should be advised that Pariet may mask symptoms of gastric cancer, and appropriate diagnostic measures should be undertaken before initiating therapy. Long-term use (particularly beyond one year) may lead to decreased magnesium levels; periodic monitoring of magnesium is recommended. There is an increased risk of bone fractures with long-term and high-dose PPI therapy, particularly in older adults. Patients should be cautioned about the potential for Clostridium difficile-associated diarrhea. Vitamin B12 deficiency may occur with long-term therapy due to decreased gastric acid. Use during pregnancy should only be if clearly needed, and caution is advised when prescribing to nursing mothers.
Contraindications
Pariet is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or any component of the formulation. It should not be used in patients taking rilpivirine-containing products due to the potential for decreased antiviral efficacy. Concomitant use with atazanavir is not recommended due to significant reduction in atazanavir exposure. Patients with a history of acute interstitial nephritis with previous PPI use should avoid Pariet.
Possible side effect
Common side effects (≥1%) include headache, diarrhea, nausea, vomiting, abdominal pain, flatulence, and constipation. Less frequently, patients may experience dizziness, rash, dry mouth, insomnia, or peripheral edema. Serious adverse reactions may include anaphylaxis, angioedema, Stevens-Johnson syndrome, acute interstitial nephritis, Clostridium difficile-associated diarrhea, hypomagnesemia, and cutaneous lupus erythematosus. Long-term use has been associated with increased risk of fundic gland polyps, vitamin B12 deficiency, and hip, wrist, or spine fractures.
Drug interaction
Pariet may decrease the absorption of drugs requiring gastric acid for optimal bioavailability, including ketoconazole, itraconazole, iron salts, and dabigatran etexilate. It may increase the exposure to methotrexate, potentially enhancing its toxicity. Concomitant use with warfarin may require increased monitoring of INR due to potential interaction. Rabeprazole may interact with CYP2C19 substrates such as phenytoin, diazepam, and clopidogrel, though its effect on clopidogrel is less pronounced than with other PPIs. Caution is advised when coadministering with tacrolimus or saquinavir.
Missed dose
If a dose of Pariet is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in dosing is important for maintaining acid control, particularly in conditions requiring continuous suppression.
Overdose
Experience with rabeprazole overdose is limited. Reported doses up to 80 mg have not resulted in severe adverse events. Potential symptoms may include confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, and diaphoresis. There is no specific antidote for rabeprazole overdose. Treatment should be supportive and symptomatic, including monitoring of vital signs and clinical status. Dialysis is not likely to be effective due to high protein binding.
Storage
Pariet tablets should be stored at room temperature (15-30°C or 59-86°F) in their original container, protected from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers that may not provide adequate protection from moisture.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Pariet is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate, discontinue, or change dosage without consulting their physician. The complete prescribing information should be consulted before use. Individual results may vary, and not all side effects or interactions are listed here.
Reviews
Clinical studies have demonstrated Pariet’s efficacy in acid suppression and symptom relief. In a randomized controlled trial involving patients with erosive GERD, 20 mg daily of rabeprazole achieved healing rates of 93% after 8 weeks of treatment. Another study showed superior symptom control compared to placebo in NERD (non-erosive reflux disease) patients. Combination therapy with rabeprazole for H. pylori eradication has shown success rates exceeding 85% in intention-to-treat analyses. Long-term maintenance studies indicate sustained efficacy in preventing relapse of erosive esophagitis with generally good tolerability. Some real-world evidence suggests potential variations in response based on CYP2C19 genotype, though rabeprazole appears less affected by metabolism status than other PPIs.